Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evotec AG ( (EVO) ) just unveiled an update.
Evotec SE announced on April 24, 2026, that Chief Financial Officer Paul Hitchin will step down for personal reasons on April 30, 2026, after overseeing a period of financial and strategic evolution since March 1, 2025. He will be succeeded by seasoned finance executive Claire Hinshelwood, currently Group Chief Finance Officer of BMI Group, who will take over as CFO on May 1, 2026, bringing extensive experience from roles at BMI Group, Novartis and Syngenta.
The transition underscores Evotec’s continued focus on advancing its ongoing business transformation toward higher profitability and sustainable growth, as highlighted by CEO Christian Wojczewski and both the outgoing and incoming CFOs. Management emphasized confidence in the company’s strategic direction and Hinshelwood’s track record in reshaping financial operations under challenging market conditions, signaling continuity for investors and partners as Evotec pursues its next phase of growth.
The most recent analyst rating on (EVO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
Spark’s Take on EVO Stock
According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.
The score is held down primarily by weak financial performance (persistent losses and negative free cash flow) and bearish longer-term technicals (below key moving averages, negative MACD). The earnings call adds partial support via cost-savings progress, strong biologics performance, and liquidity, but 2026 transition-year guidance and D&PD weakness temper the outlook; valuation is also constrained by negative earnings and no dividend yield.
To see Spark’s full report on EVO stock, click here.
More about Evotec AG
Evotec SE is a Germany-based life science company focused on drug discovery and development, integrating breakthrough science, AI-driven innovation and advanced technologies to accelerate the path from concept to cure. Its capabilities span small molecules, biologics, cell therapies and related modalities, supported by proprietary platforms and a portfolio of more than 100 co-owned R&D assets in key therapeutic areas such as oncology, cardiovascular and metabolic diseases, neurology and immunology.
The company partners with all Top 20 pharma groups, over 800 biotechs, academic institutions and healthcare stakeholders, offering models from standalone services to fully integrated R&D programs and long-term strategic alliances. Through its Just – Evotec Biologics unit, it also develops and manufactures biologics to improve accessibility and affordability, operating from sites in Europe and the U.S. with a global team of more than 4,500 experts.
Average Trading Volume: 155,301
Technical Sentiment Signal: Sell
Current Market Cap: $1.12B
For an in-depth examination of EVO stock, go to TipRanks’ Overview page.